SCHEMBL4930828

SCHEMBL4930828

CC(C)Nc1cc(F)cc(COc2c(Br)cc(C(=O)NCC(=O)O)cc2Br)c1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
THRB P10828 8/20 0.38
THRA P10827 7/20 0.38
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
MAPT P10636 2/20 0.36
DHODH Q02127 2/20 0.36
GPR139 Q6DWJ6 1/20 0.36
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
MAOB P27338 1/20 0.35
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4932371 0.92 SMN1; SMN2 (0.39) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL4928440 0.89 GPR139 (0.39) SMN1; SMN2MEN1KMT2ALMNAHPGD
SCHEMBL5116634 0.89 BRD4 (0.39) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL5717927 0.89 THRA (0.45) THRBTHRA
SCHEMBL4932258 0.89 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL5111314 0.89 SENP5 (0.40) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL4351934 0.88 THRA (0.42) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL4929610 0.88 THRA (0.40) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL4927337 0.87 THRB (0.49) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL5119983 0.87 SMN1; SMN2 (0.39) SMN1; SMN2MEN1KMT2ATHRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221210-A1 Thyroid Receptor Agonists KARO BIO AB (SE) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221210-A1 Thyroid Receptor Agonists TSHR, TRHR, THRA SMN1; SMN2 4282/4885MEN1 773/4885KMT2A 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.